<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2013-06-04" updated="2019-12-02">
  <drugbank-id primary="true">DB08898</drugbank-id>
  <name>Glucarpidase</name>
  <description>Glucarpidase is the recombinant form of the Pseudomonas sp. (strain RS-16) enzyme carboxypeptidase G2 that is produced in Escherichia coli. In patients, glucarpidase inactivates methotrexate, and other antifolates, by hydrolyzing glutamate on the carboxyl terminal of these compounds. Therefore since methotrexate is eliminated enzymatically and not by the kidneys, glucarpidase is indicated in patients on methotrexate treatment who have kidney dysfunction, and are experiencing an abnormally high plasma concentration of methotrexate (&gt;1 micromole per liter). Glucarpidase is marketed under the brand name Voraxaze®.</description>
  <cas-number>9074-87-7</cas-number>
  <unii>2GFP9BJD79</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7476</ref-id>
        <pubmed-id>23209370</pubmed-id>
        <citation>Green JM: Glucarpidase to combat toxic levels of methotrexate in patients. Ther Clin Risk Manag. 2012;8:403-13. doi: 10.2147/TCRM.S30135. Epub 2012 Nov 22.</citation>
      </article>
      <article>
        <ref-id>A7477</ref-id>
        <pubmed-id>23170306</pubmed-id>
        <citation>Tuffaha HW, Al Omar S: Glucarpidase for the treatment of life-threatening methotrexate overdose. Drugs Today (Barc). 2012 Nov;48(11):705-11. doi: 10.1358/dot.2012.48.11.1871575.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Used in patients on methotrexate treatment who have kidney dysfunction, and are experiencing an abnormally high plasma concentration of methotrexate (&gt; 1 micromole per liter).</indication>
  <pharmacodynamics>Glucarpidase acts as an antidote to toxic methotrexate levels by elminating methotrexate by a non-kidney route.</pharmacodynamics>
  <mechanism-of-action>Glucarpidase inactivates methotrexate, and other antifolates, by hydrolyzing glutamate on the carboxyl terminal of these compounds. For methotrexate specifically, it is hydrolyzed to the inactive metabolites glutamate and 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA).</mechanism-of-action>
  <toxicity>Most common adverse reactions include hypotension, flushing, nausea, vomiting, headache, and paresthesia.</toxicity>
  <metabolism>Metabolism was not determined.</metabolism>
  <absorption>In healthy patients not taking methotrexate, the average maximum concentration for glucarpidase was 3.3 μg/mL.</absorption>
  <half-life>In healthy patients not taking methotrexate, glucarpidase has an elimination half-life of 5.6 hours. In patients with severe renal impairment (creatinine clearance &lt;30 mL/min), glucarpidase has an longer elimination half-life at 8.2 hours.</half-life>
  <protein-binding>Plasma protein binding was not quantified.</protein-binding>
  <route-of-elimination>Route of elmination was not determined.</route-of-elimination>
  <volume-of-distribution>Glucarpidase is likely limited to the plasma volume since its volume of distribution is 3.6 L.</volume-of-distribution>
  <clearance>In healthy patients not taking methotrexate, glucarpidase has a clearance of 7.5 mL/min.</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Carboxypeptidase G2</synonym>
    <synonym language="english" coder="">Folate hydrolase G2</synonym>
    <synonym language="english" coder="">Glutamate carboxypeptidase</synonym>
    <synonym language="english" coder="">Pteroylmonoglutamic acid hydrolase G2</synonym>
  </synonyms>
  <products>
    <product>
      <name>Voraxaze</name>
      <labeller>BTG International Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50633-210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>1000 [USP'U]/1</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125327</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Voraxaze</name>
      <ingredients>Glucarpidase</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Carboxypeptidases</category>
      <mesh-id>D002268</mesh-id>
    </category>
    <category>
      <category>Detoxifying Agents for Antineoplastic Treatment</category>
      <mesh-id/>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Exopeptidases</category>
      <mesh-id>D020689</mesh-id>
    </category>
    <category>
      <category>gamma-Glutamyl Hydrolase, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Peptide Hydrolases</category>
      <mesh-id>D010447</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>1000 [USP'U]/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V03AF09">
      <level code="V03AF">Detoxifying agents for antineoplastic treatment</level>
      <level code="V03A">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V03">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB08898.pdf?1370406330</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB08898.pdf?1370407665</msds>
  <patents/>
  <food-interactions>
    <food-interaction>No food effects were found.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00116</drugbank-id>
      <name>Tetrahydrofolic acid</name>
      <description>The serum concentration of the active metabolites of Tetrahydrofolic acid can be reduced when Tetrahydrofolic acid is used in combination with Glucarpidase resulting in a loss in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic acid</name>
      <description>The serum concentration of the active metabolites of Folic acid can be reduced when Folic acid is used in combination with Glucarpidase resulting in a loss in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00650</drugbank-id>
      <name>Leucovorin</name>
      <description>The serum concentration of the active metabolites of Leucovorin can be reduced when Leucovorin is used in combination with Glucarpidase resulting in a loss in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02031</drugbank-id>
      <name>(6S)-5,6,7,8-tetrahydrofolic acid</name>
      <description>The serum concentration of the active metabolites of (6S)-5,6,7,8-tetrahydrofolic acid can be reduced when (6S)-5,6,7,8-tetrahydrofolic acid is used in combination with Glucarpidase resulting in a loss in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02067</drugbank-id>
      <name>Triglu-5-formyl-tetrahydrofolate</name>
      <description>The serum concentration of the active metabolites of Triglu-5-formyl-tetrahydrofolate can be reduced when Triglu-5-formyl-tetrahydrofolate is used in combination with Glucarpidase resulting in a loss in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03256</drugbank-id>
      <name>(6R)-Folinic acid</name>
      <description>The serum concentration of the active metabolites of (6R)-Folinic acid can be reduced when (6R)-Folinic acid is used in combination with Glucarpidase resulting in a loss in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04789</drugbank-id>
      <name>5-methyltetrahydrofolic acid</name>
      <description>The serum concentration of the active metabolites of 5-methyltetrahydrofolic acid can be reduced when 5-methyltetrahydrofolic acid is used in combination with Glucarpidase resulting in a loss in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11256</drugbank-id>
      <name>Levomefolic acid</name>
      <description>The serum concentration of the active metabolites of Levomefolic acid can be reduced when Levomefolic acid is used in combination with Glucarpidase resulting in a loss in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11596</drugbank-id>
      <name>Levoleucovorin</name>
      <description>The serum concentration of the active metabolites of Levoleucovorin can be reduced when Levoleucovorin is used in combination with Glucarpidase resulting in a loss in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00293</drugbank-id>
      <name>Raltitrexed</name>
      <description>The metabolism of Raltitrexed can be increased when combined with Glucarpidase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The metabolism of Methotrexate can be increased when combined with Glucarpidase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The metabolism of Pemetrexed can be increased when combined with Glucarpidase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>The metabolism of Pralatrexate can be increased when combined with Glucarpidase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12769</drugbank-id>
      <name>Lometrexol</name>
      <description>The metabolism of Lometrexol can be increased when combined with Glucarpidase.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt; Glucarpidase
ALAQKRDNVLFQAATDEQPAVIKTLEKLVNIETGTGDAEGIAAAGNFLEAELKNLGFTVT
RSKSAGLVVGDNIVGKIKGRGGKNLLLMSHMDTVYLKGILAKAPFRVEGDKAYGPGIADD
KGGNAVILHTLKLLKEYGVRDYGTITVLFNTDEEKGSFGSRDLIQEEAKLADYVLSFEPT
SAGDEKLSLGTSGIAYVQVNITGKASHAGAAPELGVNALVEASDLVLRTMNIDDKAKNLR
FNWTIAKAGNVSNIIPASATLNADVRYARNEDFDAAMKTLEERAQQKKLPEADVKVIVTR
GRPAFNAGEGGKKLVDKAVAYYKEAGGTLGVEERTGGGTDAAYAALSGKPVIESLGLPGF
GYHSDKAEYVDISAIPRRLYMAARLIMDLGAGK</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Molecular Weight</kind>
      <value>44016.6653</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C1950H3157N543O599S7</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910382</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D10260</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P06621</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Glucarpidase</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1863515</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/voraxaze-drug.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/mtm/glucarpidase.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004838</id>
      <name>Methotrexate</name>
      <organism>Humans</organism>
      <actions>
        <action>metabolizer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17958</ref-id>
            <pubmed-id>15668713</pubmed-id>
            <citation>Buchen S, Ngampolo D, Melton RG, Hasan C, Zoubek A, Henze G, Bode U, Fleischhack G: Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer. 2005 Feb 14;92(3):480-7.</citation>
          </article>
          <article>
            <ref-id>A7477</ref-id>
            <pubmed-id>23170306</pubmed-id>
            <citation>Tuffaha HW, Al Omar S: Glucarpidase for the treatment of life-threatening methotrexate overdose. Drugs Today (Barc). 2012 Nov;48(11):705-11. doi: 10.1358/dot.2012.48.11.1871575.</citation>
          </article>
          <article>
            <ref-id>A7476</ref-id>
            <pubmed-id>23209370</pubmed-id>
            <citation>Green JM: Glucarpidase to combat toxic levels of methotrexate in patients. Ther Clin Risk Manag. 2012;8:403-13. doi: 10.2147/TCRM.S30135. Epub 2012 Nov 22.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>